March 15, 2019 – Avricore Health Inc. (“AVCR”), is pleased to announce that further to its news release dated February 13, 2019, it has closed a non-brokered private placement of 4,206,435 common shares (“Common Shares”) of the Company at a price of $0.07 per Common Share for gross proceeds of approximately CDN$294,451 (the “Offering”).

The Offering included participation by a number of AVCR’s officers and directors. Proceeds from the Offering are planned to be used by AVCR for corporate overhead and working capital. No commission or compensation warrants have been paid or issued in connection with the Offering. The securities issued pursuant to the Offering are subject to a four (4) month hold period and
completion of the Offering is subject to all required regulatory approvals, including final acceptance by
the TSX Venture Exchange.

Contact:
Bob Rai, Director and CEO
604-247-2639
info@avricorehealth.com
www.avricorehealth.com
About Avricore Health Inc.
Avricore Health Inc. is committed to becoming a health innovator and applying technologies at the forefront of science to core health issues at the community pharmacy level. The Company’s goal is to empower consumers, patients and pharmacists with innovative technology, products, services and information to monitor and optimize health. www.avricorehealth.com
Cautionary Note Regarding Forward-Looking Statements: Information in this press release that involves Avricore Health’s
expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve
a number of risks and uncertainties. Avricore Health generally uses words such as “outlook,” “will,” “could,” “would,” “might,”
“remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “plan,” “positioned,”
“potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify
forward-looking statements. In this press release, forward-looking statements include statements regarding: the integration of
Molecular You’s service offerings with the HealthTab platform; the unique features that the HealthTab platform offers to
pharmacists and patients; the emergence of pharmacist managed health initiatives and the potentially lucrative opportunities
in connection therewith; the opportunity for pharmacists to play a key role in helping patients achieve nutritional and dietary
objectives; and the anticipated benefits of the HealthTab/Molecular You combination to pharmacists and patients. Forwardlooking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health’s management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be
incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of
risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially
Avricore Health Inc. | 2639 Viking Way, Suite 210, Richmond, B.C. V6V 3B7, Canada www.AvricoreHealth.com
from current expectations, including without limitation: failure to negotiate and enter into a definitive agreement with
Molecular You; failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions;
and other risk factors described in Avricore Health’s public filings available on SEDAR at www.sedar.com. Accordingly, readers
should exercise caution in relying upon forward-looking statements and Avricore Health undertakes no obligation to publicly
revise them to reflect subsequent events or circumstances, except as required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.